Lyra Therapeutics Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Maria Palasis
Chief Executive Officer (CEO)
US$1.8m
Compensación total
| Porcentaje del salario del CEO | 32.7% |
| Permanencia del CEO | 9.3yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 2.2yrs |
| Promedio de permanencia en la Junta Directiva | 3.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?
Jan 25
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully
Sep 10Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 12Lyra Therapeutics appoints Nieman as Chief Medical Officer
Jul 05Lyra Therapeutics: Progress In The Clinic
May 18A First Look At Lyra Therapeutics
Apr 21Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
Mar 30Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?
Dec 14We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth
Aug 28We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate
May 04How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?
Mar 05Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth
Jan 11
Lyra Therapeutics down 19% underwhelming data from lead program
Dec 07Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis
Nov 24Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$583k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$62m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$60m |
| Dec 31 2022 | US$2m | US$583k | -US$55m |
| Sep 30 2022 | n/a | n/a | -US$55m |
| Jun 30 2022 | n/a | n/a | -US$51m |
| Mar 31 2022 | n/a | n/a | -US$48m |
| Dec 31 2021 | US$2m | US$552k | -US$44m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$26m |
| Dec 31 2020 | US$4m | US$471k | -US$22m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$18m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$843k | US$388k | -US$17m |
Compensación vs. Mercado: La compensación total ($USD1.79M) de Maria está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.37M).
Compensación vs. Ingresos: La compensación de Maria ha aumentado mientras la empresa no es rentable.
CEO
Maria Palasis (58 yo)
9.3yrs
Permanencia
US$1,785,375
Compensación
Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 2.2yrs | US$625.06k | 0.44% $ 1.4m | |
| CEO, President & Director | 9.3yrs | US$1.79m | sin datos | |
| Chief Technology Officer | 1.2yrs | US$1.03m | sin datos | |
| Co-Founder | no data | sin datos | sin datos | |
| CFO, Treasurer & Secretary | 2.6yrs | US$1.07m | sin datos | |
| Vice President of Operations | no data | sin datos | sin datos | |
| Senior Vice President of Investor Relations & Communications | 1.6yrs | sin datos | sin datos | |
| Chief Legal Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Commercial Strategy & Market Development | 5.6yrs | US$653.33k | sin datos | |
| Senior Vice President of Clinical Affairs | no data | sin datos | sin datos | |
| Senior Vice President of Technical Operations | 1.2yrs | US$666.79k | sin datos | |
| Chief Clinical Advisor | 3.2yrs | sin datos | sin datos |
2.2yrs
Permanencia media
56.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de LYRA se considera experimentado (2.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 2.2yrs | US$625.06k | 0.44% $ 1.4m | |
| CEO, President & Director | 9.3yrs | US$1.79m | sin datos | |
| Lead Independent Director | 2.1yrs | US$152.31k | 0% $ 0 | |
| Independent Director | 4.4yrs | US$123.81k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.5yrs | US$333.93k | sin datos | |
| Independent Director | 4.6yrs | US$113.06k | 0.019% $ 59.0k | |
| Member of Scientific Advisory Board | 3.5yrs | US$19.36k | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos |
3.5yrs
Permanencia media
72yo
Promedio de edad
Junta con experiencia: La junta directiva de LYRA se considera experimentada (3.5 años de antigüedad promedio).